← Back to patent-cliff list
Lornoxicam
Tier C — Watch / tradeLornoxicam
F. Hoffmann-La Roche
Originator
1997
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：COXs
Brand：Telos, Acabel, Lorcam, Bosporon, Xefocam, Xafon, Taigalor, Xefo, Safem
Indications (approved)：风湿性疾病, Osteoarthritis, 神经痛, Postoperative pain, Pain, 关节周围炎, 颈肩腕综合征, Rheumatoid arthritis
Regional status
US
No progress
2005-12-01
EU
Approved
1997-01-01
China
Approved
2001-06-29
Japan
Approved
2000-12-22
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Lornoxicam?
Approved indications include: 风湿性疾病, Osteoarthritis, 神经痛, Postoperative pain, Pain, 关节周围炎, 颈肩腕综合征, Rheumatoid arthritis.
When does the Lornoxicam patent expire?
No public expiry year is available for Lornoxicam yet; this page updates once verified.
How do I get a quote for Lornoxicam intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27